Humacyte, Inc.

Humacyte, Inc. (Nasdaq: HUMA) is a clinical-stage regenerative medicine company that became publicly listed through its 2021 business combination with Alpha Healthcare Acquisition Corp., a special purpose acquisition company sponsored by Alpha Healthcare Partners that completed its IPO in 2020 on Nasdaq targeting the healthcare and life sciences sector. Humacyte focuses on developing human acellular vessels for vascular repair and reconstruction. The company filed an 8-K with the SEC on June 11, 2025, under accession number 0001818382-25-000080, reflecting ongoing public reporting obligations as a post-combination listed issuer. For full filing data, historical SPAC metrics, and real-time monitoring on HUMA and thousands of other SPAC-linked companies, sign up for SpacDesk.